Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors

Trial Profile

Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Kyowa Hakko Kirin; Ono Pharmaceutical
  • Most Recent Events

    • 22 Jan 2018 Planned End Date changed to 1 Oct 2019.
    • 21 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2019.
    • 16 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top